News - GlaxoSmithKline, Eli Lilly

Filter

Current filters:

GlaxoSmithKlineEli Lilly

Popular Filters

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

22-04-2014

In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

13-01-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to amend…

Asia-PacificBridionEli LillyFinancialGlaxoSmithKlineHealthcareLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalStrattera

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide

24-06-2013

Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Important decision for the biotech industry from UK Supreme Court

03-11-2011

The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions

04-10-2011

The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top